Literature DB >> 16439772

The origins of cachexia in acute and chronic inflammatory diseases.

Matthew J Delano1, Lyle L Moldawer.   

Abstract

The term cachexia originates from the Greek root kakos hexis, which translates into "bad condition," recognized for centuries as a progressive deterioration of body habitus. Cachexia is commonly associated with a number of disease states, including acute inflammatory processes associated with critical illness and chronic inflammatory diseases, such as cancer, congestive heart failure, chronic obstructive pulmonary disease, and human immunodeficiency virus infection. Cachexia is responsible for the deaths of 10%-22% of all patients with cancer and approximately 15% of the trauma deaths that occur from sepsis-induced organ dysfunction and malnutrition days to weeks after the initial traumatic event. The abnormalities associated with cachexia include anorexia, weight loss, a preferential loss of somatic muscle and fat mass, altered hepatic glucose and lipid metabolism, and anemia. Anorexia alone cannot fully explain the development of cachexia; metabolic alterations in carbohydrate, lipid, and protein metabolism contribute to the severe tissue losses. Despite significant advances in our understanding of specific disease processes, the mechanisms leading to cachexia remain unclear and multifactorial. Although complex, increasing evidence from both animal models and clinical studies suggests that an inflammatory response, mediated in part by a dysregulated production of proinflammatory cytokines, plays a role in the genesis of cachexia, associated with both critical illness and chronic inflammatory diseases. These cytokines are further thought to induce an acute phase protein response (APR) and produce the alterations in lipid and carbohydrate metabolism identified as crucial markers of acute inflammation in states of malignancy and critical illness. Although much is still unknown about the etiology of cachexia, there is growing appreciation that cachexia represents the endproduct of an inappropriate interplay between multiple cytokines, neuropeptides, classic stress hormones, and intermediary substrate metabolism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439772     DOI: 10.1177/011542650602100168

Source DB:  PubMed          Journal:  Nutr Clin Pract        ISSN: 0884-5336            Impact factor:   3.080


  52 in total

1.  Preliminary development of a lymphedema symptom assessment scale for patients with head and neck cancer.

Authors:  Jie Deng; Sheila H Ridner; Barbara A Murphy; Mary S Dietrich
Journal:  Support Care Cancer       Date:  2011-11-10       Impact factor: 3.603

2.  The dose-dependent effects of endotoxin on protein metabolism in two types of rat skeletal muscle.

Authors:  Miroslav Kovarik; Tomas Muthny; Ludek Sispera; Milan Holecek
Journal:  J Physiol Biochem       Date:  2012-02-07       Impact factor: 4.158

3.  An intermediate dose of LCMV clone 13 causes prolonged morbidity that is maintained by CD4+ T cells.

Authors:  Andrew Stamm; Laura Valentine; Rashaun Potts; Mary Premenko-Lanier
Journal:  Virology       Date:  2012-02-04       Impact factor: 3.616

4.  Rel A/p65 is required for cytokine-induced myotube atrophy.

Authors:  Takuo Yamaki; Chia-Ling Wu; Michael Gustin; Jamie Lim; Robert W Jackman; Susan C Kandarian
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-16       Impact factor: 4.249

5.  NF-kappaB signaling in the aging process.

Authors:  Antero Salminen; Kai Kaarniranta
Journal:  J Clin Immunol       Date:  2009-05-01       Impact factor: 8.317

6.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

Review 7.  The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature.

Authors:  Hánah N Rier; Agnes Jager; Stefan Sleijfer; Andrea B Maier; Mark-David Levin
Journal:  Oncologist       Date:  2016-07-13

8.  Malnutrition, associated clinical factors, and depression in systemic sclerosis: a cross-sectional study.

Authors:  İpek Türk; Nihan Cüzdan; Volkan Çiftçi; Didem Arslan; Muharrem Cem Doğan; İlker Unal
Journal:  Clin Rheumatol       Date:  2019-05-26       Impact factor: 2.980

9.  Endotoxin and interferon-gamma inhibit translation in skeletal muscle cells by stimulating nitric oxide synthase activity.

Authors:  Robert A Frost; Gerald J Nystrom; Charles H Lang
Journal:  Shock       Date:  2009-10       Impact factor: 3.454

10.  JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome.

Authors:  Kathryn D Tuttle; Katherine A Waugh; Paula Araya; Ross Minter; David J Orlicky; Michael Ludwig; Zdenek Andrysik; Matthew A Burchill; Beth A J Tamburini; Colin Sempeck; Keith Smith; Ross Granrath; Dayna Tracy; Jessica Baxter; Joaquin M Espinosa; Kelly D Sullivan
Journal:  Cell Rep       Date:  2020-11-17       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.